Pharmacotherapeutic efficiency and advantages of the combined treatment of patients with type 2 diabetes mellitus
Journal Title: Міжнародний ендокринологічний журнал - Year 2017, Vol 13, Issue 6
Abstract
Background. The early prescription of a combination of extended-release metformin with glimepiride influencing different links of the pathogenesis of type 2 diabetes mellitus (DM) is grounded in the article. The purpose of the research was to evaluate the dynamics of glycated haemoglobin (HbA1c) after the period of supervision as compared to the baseline, and also to determine additional parameters of efficiency, safety, and tolerability of Duglimax manufactured by Кusum Pharm (Ukraine) in the therapy of type 2 DM. Materials and methods. The study included 46 patients with type 2 DM divided into two groups. For the patients of the first group (n = 26), who previously received metformin preparations at a dose of up to 2000 mg/day, the combined preparation Duglimax (metformin 500 mg and glimepiride 2 mg) was prescribed, and also extended-release metformin (Metamin SR) in the evening. The patients of the second group (n = 20) continued the reception of extended-release metformin twice daily in a dose of 2000–2500 mg/day. Results. After 12 weeks of therapy, in patients of the first group, the level of НbА1с significantly decreased to 6.72 ± 0.29 %. The level of insulin in the first group was 14.06 ± 1.81 mIU/ml after treatment (in baseline level of 19.17 ± 2.05 mIU/ml), HOMA-IR — 3.14 ± 0.21 (vs initial one of 5.92 ± 1.46). Results of the clinical study show the absence of hypoglycemia development in patients receiving Duglimax during the follow-up period. Conclusions. Combined antidiabetic therapy with Duglimax for 12 weeks results in the substantial decrease of HbA1c level and achievement of target indexes of carbohydrate metabolism in type 2 DM patients. The good tolerability and high safety of Duglimax were registered during the period of supervision.
Authors and Affiliations
V. I. Pankiv
Keywords
Related Articles
- EP ID EP231286
- DOI 10.22141/2224-0721.13.6.2017.112887
- Views 52
- Downloads 0
Combination Therapy «Metformin + Glimepiride» in Patients with Type 2 Diabetes Mellitus (Molecular Mechanisms for Optimization of the Rehabilitation Effect)
This review describes the molecular mechanisms of therapeutic action of the combination of oral antidiabetic drugs «metformin + glimepiride», aimed at the correction of both defects, which determine the development of me...
Diabetes Mellitus: Diagnostic Criteria, Etiology and Pathogenesis
.
Lifestyle Change as a Part of Complex Therapy of Chronic Systemic Inflammation in Metabolic Syndrome
From a perspective of integrative physiology, metabolic syndrome (MS) can be regarded as a syntropy of internal diseases, based on the systemic inflammation, insulin resistance, lipotoxicity and other processes which dep...
Vitamin D status, frequency of its insufficiency and deficiency in women with polycystic ovary syndrome
Background. Many studies have investigated vitamin D status in women with polycystic ovary syndrome (PCOS), but there is no consensus on whether or not its serum levels are different between women with and without PCOS....
Current Views on the Treatment Algorithm in Patients with Diabetes Mellitus and Erectile Dysfunction
Diabetes mellitus (DM) is common throughout the world. According to the World Health Organization’s data, there are about 415 millions of patients with DM now in the world, and their number is growing significantly. The...